Recent research presented at the annual IDWeek meeting in Los Angeles has raised critical questions surrounding the efficacy of tecovirimat (marketed as Tpoxx) in treating mpox. The PALM007 trial, a randomized and placebo-controlled study conducted in the Democratic Republic of the Congo (DRC), suggests that tecovirimat does not significantly affect the duration of mpox lesions
Your Source For Global News Stories